Abstract

Background Recent advances in cancer immunology are found on many frontiers on targeting cancer and cancer niches with conjugated or unconjugated monoclonal antibodies and by activating immune responses via antibodies antigens and vaccines cytokines costimulatory pathways and checkpoint modulators or by adoptive cell transfer like CAR T often in combinatorial treatments The field has quickly carved out a new 50 billion dollar biologics industry that will double again in only 4-5 years It is a topic of immense economic societal political scientific healthcare related and biomedical interest Despite this unbiased holistic overviews of the new cancer immunotherapies are widely missing Methods This scientific review begins with a brief market research to summarize approved cancer immune-therapeutics including their prospective sales estimates to structure a holistic scientific review and an in-depth research expert strategy discourse that provides a new systematic overview of the recent advances in cancer immunotherapy by revealing both its progress and bias Results This review provides a holistic scientific dossier with far-reaching economic and R D implications of the recent advances and summarizes the progress and bias in cancer immunology and immunotherapy The ambidextrous balance of explorative and exploitative progress has been biased in academia the industry and by FDA and EMA regulators many new blockbusters are now selling while the molecular mechanisms are still not fully explored for the new promising biologics strategies Conclusion Today s first-generation cancer immunetherapeutics have only partially solved the histocompatibility defiance retaining refractoriness of cancer progression-free survival and overall survival have slightly improved but costbenefit ratios are still too low and serious adverse reactions are still too frequent Malicious consulting has caused systemic biases and artificial blockades for postdocs in mana